archive-com.com » COM » A » AGENDIA.COM

Total: 235

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • News and Press Releases | Agendia - Part 4
    Continued Agendia Announces Study Showing Molecular Subtyping Can Improve Breast Cancer Treatment 09 02 2014 IRVINE CA and AMSTERDAM In findings that may eventually change the way breast cancer is evaluated and treated a new study reports that the BluePrint genomic test provides more accurate information about the molecular subtype of a specific breast Continued Agendia Co Founder and CSO Develops Method to Identify Women Who Will Benefit from Tamoxifen Therapy for Breast Cancer 07 31 2014 IRVINE CA and AMSTERDAM July 31 2014 Innovative research by Rene Bernards Ph D the co founder of Agendia Inc has identified a gene signature that has potential to identify which patients will benefit from tamoxifen therapy Bernards research appears in Continued Agendia and CBLPath Announce Agreement to Assist Physicians in Diagnostic Assessment of Breast Cancer 07 16 2014 IRVINE CA AMSTERDAM and Rye Brook N Y July 16 2014 Agendia a leading molecular diagnostics company and CBLPath Inc a leading pathology services provider today announced they have agreed to collaborate in providing molecular diagnostics testing to breast cancer Continued Value of Breast Cancer Molecular Subtyping Documented by Independent Study Comparing Genomic Tests at ASCO 2014 Meeting 06 10 2014 IRVINE CA and

    Original URL path: http://www.agendia.com/agendia-news-and-press-releases/page/4/ (2016-05-01)
    Open archived version from archive

  • News and Press Releases | Agendia - Part 5
    Continued Multiple Studies on Agendia s MammaPrint and BluePrint Tests to Be Featured at ASCO Annual Meeting 05 22 2014 IRVINE CA and AMSTERDAM THE NETHERLANDS May 22 2014 New research involving Agendia s genomic tests MammaPrint BluePrint TargetPrint and TheraPrint as well as its ColoPrint Colon Cancer Genomic Profile will be reported at the 2014 annual meeting of the American Continued Molecular Subtyping with Agendia Tests Can Provide Better Guidance for Breast Cancer Treatment New Research Reports 05 06 2014 Presentations to American Society of Breast Surgeons Detail Clinical Insights from MammaPrint and BluePrint Genomic Tests IRVINE CA and AMSTERDAM May 7 2014 New evidence showing that the MammaPrint and BluePrint tests provide insights into how to treat breast Continued Agendia Announces New Agreement with Daiichi Sankyo to Support Oncology Drug Development 04 24 2014 Companies Will Apply Agendia Oncology Biomarker Expertise to Daiichi Sankyo Pharmaceutical Research IRVINE CA and AMSTERDAM April 24 2014 Agendia today announced a new agreement with Daiichi Sankyo regarding oncology drug development and personalized medicine The agreement calls for Continued Agendia Announces New Data at European Breast Cancer Conference that Further Supports Use of MammaPrint and BluePrint Tests 03 26 2014 Presentation Shows MammaPrint

    Original URL path: http://www.agendia.com/agendia-news-and-press-releases/page/5/ (2016-05-01)
    Open archived version from archive

  • Multiple Studies on Agendia’s MammaPrint and BluePrint Tests to Be Featured at ASCO Annual Meeting | Agendia
    consult the following all times are Central Daylight Time Breast cancer POSTER PRESENTATION MINT Multi Institutional Neo Adjuvant Therapy MammaPrint Project Abstract TPS1137 Lead Author Charles E Cox M D Breast Health Program University of South Florida College of Medicine Session Title Breast Cancer Triple Negative Cytotoxics Local Therapy Date Monday June 2 2014 Time 8 00 a m 11 45 a m Location S Hall A2 Poster Board 228B POSTER PRESENTATION Chemosensitivity and endocrine sensitivity predicted by MammaPrint and BluePrint in the Neo adjuvant Breast Registry Symphony Trial NBRST Abstract 1078 Lead Author Pat W Whitworth M D Nashville Breast Center Session Title Breast Cancer Triple Negative Cytotoxics Local Therapy Date Monday June 2 2014 Time 8 00 a m 11 45 a m Location S Hall A2 Poster Board 171 POSTER PRESENTATION Genomic profiling of breast cancer in African American women Abstract 11067 Lead Author Racquel Nunes M D Washington Cancer Institute Session Title Tumor biology Date Saturday May 31 2014 Time 1 15 p m 5 00 p m Location S Hall A2 Poster Board 349 POSTER HIGHLIGHTS PRESENTATION Biomarker panel TheraPrint analyzed as predictor of response to neo adjuvant chemotherapy in patients with locally advanced breast cancer Abstract 1026 Lead Author Peter D Beitsch M D FACS Medical City Dallas Hospital Session Title Breast Cancer Triple Negative Cytotoxics Local Therapy Date Monday June 2 2014 Time 1 15 p m 4 15 p m Location E354b Poster Board 19 POSTER PRESENTATION Comparison of test results and clinical outcomes of patients assessed with both MammaPrint and Oncotype DX with pathologic variables an independent study Abstract 550 Lead Author David J Dabbs M D Chief of Pathology Magee Womens Hospital University of Pittsburgh Medical Center Session Title Breast Cancer HER2 ER Date Monday June 2 2014 Time 8 00 a m 11 45 a m Location S Hall A2 Poster Board 14 Colon cancer ORAL PRESENTATION Colorectal cancer subtyping consortium CRCSC identifies consensus of molecular subtypes Abstract 3511 Lead Author Rodrigo Dienstmann Ph D M D Research Scientist Sage Bionetworks Session Title Colorectal Cancer Not Just One Disease Session Type Clinical Science Symposium Date Tuesday June 3 2014 Time 10 21 a m 10 33 a m Session time 9 45 a m 11 15 a m Location S406 POSTER PRESENTATION Molecular subtyping of colorectal cancer identifies patients with a mesenchymal tumor type who might benefit from TGF beta inhibition Abstract 3618 Lead Author Ramon Salazar M D Ph D Catalan Institute of Oncology L Hospitalet de Llobregat Barcelona Spain Session Title Gastrointestinal Colorectal Cancer Date Saturday May 31 2014 Time 8 00 a m 11 45 a m Location S Hall A2 Poster Board 81 POSTER PRESENTATION Comparison of ColoPrint risk classification with clinical risk in the prospective PARSC trial Abstract 3562 Lead Author Ramon Salazar M D Ph D Catalan Institute of Oncology L Hospitalet de Llobregat Barcelona Spain Session Title Gastrointestinal Colorectal Cancer Date Saturday May 31 2014 Time 8 00 a m 11 45

    Original URL path: http://www.agendia.com/multiple-studies-on-agendias-mammaprint-and-blueprint-tests-to-be-featured-at-asco-annual-meeting-2/ (2016-05-01)
    Open archived version from archive

  • Agendia Announces New Agreement with Daiichi Sankyo to Support Oncology Drug Development | Agendia
    said David Macdonald Agendia s President and CEO We are very pleased to apply our expertise to assist with the potentially groundbreaking work being done by Daiichi Sankyo Macdonald noted that Agendia has a long history of providing clinically valuable information about gene expression in oncology With this new agreement our molecular diagnostics technology will now be applied to additional areas of oncology research he said As part of the agreement between Agendia and Daiichi Sankyo Agendia technology will be used to assess patient samples Terms and other aspects of the agreement were not disclosed Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified unmet medical needs of patients in both mature and emerging markets For more information visit www daiichisankyo com About Agendia Agendia is a leading molecular diagnostic company that develops and markets FFPE based genomic diagnostic products which help support physicians with their complex treatment decisions Agendia s breast cancer suite was developed using an unbiased gene selection by analyzing the complete human genome This includes MammaPrint as well as BluePrint a molecular subtyping assay that provides deeper insight leading to more clinically actionable biology and TargetPrint an ER PR HER2 expression assay MammaPrint is the only breast cancer recurrence assay back by peer reviewed prospective outcome data These tests can help physicians assess a patient s individual risk for metastasis which patients may benefit from chemo hormonal or combination therapy and which patients may not require these treatments and can instead be treated with other less arduous and less costly methods In addition Agendia has a pipeline of other genomic products in development The company collaborates with pharmaceutical companies leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is

    Original URL path: http://www.agendia.com/agendia-announces-new-agreement-with-daiichi-sankyo-to-support-oncology-drug-development/ (2016-05-01)
    Open archived version from archive

  • Agendia Announces New Data at European Breast Cancer Conference that Further Supports Use of MammaPrint and BluePrint Tests | Agendia
    site MINDACT study a clinical trial comparing MammaPrint to standard clinical pathology factors In a fourth presentation a scientific poster from Dutch researchers demonstrated that physicians ordering the MammaPrint test are likely to follow its recommendations about whether or not adjuvant chemotherapy is advisable The study regarding MammaPrint s ability to stratify a breast cancer patient s recurrence risk for up to 25 years referenced above looked at two key measures regarding a set of 295 patients distant metastasis free survival DMFS and overall survival The accuracy of MammaPrint results held true for both DMFS and overall survival Median follow up on these patients was 18 5 years far longer than had previously been reported for a test of this kind The MINDACT podium presentation was by Fatima Cardoso M D M Sc of Champalimaud Cancer Center in Lisbon Portugal She summarized research from 119 MINDACT trial sites in Belgium Italy Holland and Portugal MINDACT is a multi center prospective phase III randomized study that examines the role of MammaPrint in adding clinically useful information about tumor biology and assessment of recurrence risk beyond information provided by standard clinical pathology such as tumor size and grade patient age number of involved lymph nodes and ER PR HER2 status These presentations featured exciting new research that shows the central role the Symphony tests can play in gaining a deeper clinically useful understanding of the breast cancer biology and tumor subtypes at the molecular level said Neil Barth M D a leading oncologist and Chief Medical Officer at Agendia MammaPrint which is included in the guidelines of the European Society for Medical Oncology ESMO uncovers more clinically actionable biology providing invaluable clinical information about an individual woman s breast cancer and whether she is likely to experience a recurrence The test delivers definitive High Risk or Low Risk information about the risk of recurrence with no ambiguous intermediate results It is the only assay providing risk recurrence information that is based on prospective trials including peer reviewed patient outcome data the RASTER study MammaPrint which in its fresh tissue format has received five 510 k FDA clearances is performed as part of Agendia s Symphony suite of breast cancer tests which also includes BluePrint the most widely available test providing molecular subtyping of individual breast cancers MammaPrint has reimbursement arrangements collectively covering approximately 188 million lives in the U S including Medicare and contracts with a number of commercial payers and is reimbursed in certain countries outside of the U S pursuant to regional coverage arrangements The 9th EBCC conference was held in Glasgow U K March 19 21 2014 About Agendia Agendia is a leading molecular diagnostic company that develops and markets FFPE based genomic diagnostic products which help support physicians with their complex treatment decisions Agendia s breast cancer Symphony suite was developed using unbiased gene selection analyzing the complete human genome Symphony includes MammaPrint as well as BluePrint a molecular subtyping assay and TargetPrint an ER PR HER2 expression

    Original URL path: http://www.agendia.com/agendia-announces-new-data-at-european-breast-cancer-conference-that-further-supports-use-of-mammaprint-and-blueprint-tests/ (2016-05-01)
    Open archived version from archive

  • News and Press Releases | Agendia - Part 6
    Test for Molecular Subtyping of Breast Cancer Shown to Better Identify Risk of Disease Recurrence 03 11 2014 Scientific Poster and Symposium at Miami Breast Cancer Conference Demonstrate Value of MammaPrint and BluePrint Tests Compared to First Generation Test IRVINE CA and AMSTERDAM March 11 2014 A scientific poster comparing Agendia s MammaPrint and BluePrint tests to the 21 gene test Continued Agendia Announces Upcoming Presentation of New Breast Cancer Data on Molecular Subtyping 02 27 2014 IRVINE CA and AMSTERDAM THE NETHERLANDS February 27 2014 A scientific poster and lunch symposium at the upcoming Miami Breast Cancer Conference will focus new attention on genomic testing and molecular subtyping to refine breast cancer treatment The poster by Continued Published Study Validates Agendia s MammaPrint Test for Long Term Prediction of Breast Cancer Outcome 02 17 2014 Researchers Conclude Molecular Test Is Able to Differentiate High and Low Recurrence Risk up to 25 Years after Diagnosis Further Validating NEJM Study IRVINE CA and AMSTERDAM THE NETHERLANDS February 17 2014 A newly published study concludes that the MammaPrint Continued Agendia s MammaPrint BluePrint Tests for Breast Cancer Highlighted at Personalized Medicine Conference 01 30 2014 Next Generation Genomic Tests Determine Molecular Subtypes

    Original URL path: http://www.agendia.com/agendia-news-and-press-releases/page/6/ (2016-05-01)
    Open archived version from archive

  • Agendia Test for Molecular Subtyping of Breast Cancer Shown to Better Identify Risk of Disease Recurrence | Agendia
    subtype and therefore at higher risk of recurrence Dr Blumencranz is the Medical Director of Comprehensive Breast Program and Cancer Services for Morton Plant Mease Health Care and Medical Director of Moffitt Morton Plant Mease Cancer Care Molecular subtyping classifies breast cancer tumors into one of four genetically distinct categories or subtypes Luminal A Luminal B Basal a subset of triple negative and HER2 type Each subtype responds to certain kinds of treatments and not others Some subtypes are also associated with a higher risk of disease recurrence which can also affect treatment choices In particular women at high risk of recurrence are usually counseled to receive chemotherapy Women at low risk can choose to forgo chemotherapy and its potentially damaging side effects and still expect a good outcome For the scientific poster researchers examined tumor samples from a study population of 148 patients The greatest discordance between MammaPrint and the 21 gene test about recurrence risk was found among 33 of the patients Those patients were stratified by the latter test as being at low risk of recurrence but MammaPrint identified them as being at a high risk of recurrence In an attempt to explain this discrepancy BluePrint was used to determine the molecular subtype of the tumors with discordant results The overwhelming number of patients classified as low risk by the 21 gene assay but as high risk by MammaPrint turned out to have the Luminal B subtype which confers a high risk of recurrence This new scientific poster has important implications for clinical practice said Agendia s Chief Medical Officer oncologist Neil Barth M D When breast cancer patients and their physicians are trying to decide whether chemotherapy would be beneficial it is crucial that they know the molecular subtype of the cancer The MammaPrint and BluePrint tests together provide this additional information about tumor biology while the older first generation test does not and may in fact supply inaccurate information about a patient s risk of recurrence The lunchtime symposium at the Miami conference was titled Molecular Subtypes Clinical Implications for Breast Cancer Patients in Your Practice The featured speaker was Massimo Cristofanilli M D a noted oncologist who described recent research at his institution and several other noted cancer centers Researchers reported that molecular subtyping with MammaPrint and BluePrint was more effective than traditional clinical pathology methods for identifying women who will not benefit from chemotherapy after breast cancer surgery These women may therefore safely forego chemotherapy and its side effects They concluded that oncologists who relied exclusively on clinical pathology subtyping with IHC FISH would have misclassified a substantial number of these patients potentially leading to overtreatment with chemotherapy in some cases and undertreatment in others The research was first presented at the 2013 San Antonio Breast Cancer Symposium SABCS MammaPrint uncovers more treatable biology providing invaluable clinical information about an individual woman s breast cancer and whether she is likely to experience a recurrence of the disease The test delivers definitive High Risk

    Original URL path: http://www.agendia.com/agendia-test-for-molecular-subtyping-of-breast-cancer-shown-to-better-identify-risk-of-disease-recurrence/ (2016-05-01)
    Open archived version from archive

  • Agendia Announces Upcoming Presentation of New Breast Cancer Data on Molecular Subtyping | Agendia
    Agendia will be Massimo Cristofanilli M D a noted oncologist Recent studies by Dr Cristofanilli and others have concluded that molecular subtyping provides a more precise prognosis and gives physicians valuable guidance about the best treatment course for early stage breast cancer Dr Cristofanilli is a leading researcher on genomic testing and molecular subtyping He directs the Breast Care Center at Thomas Jefferson University Hospitals in Philadelphia Agendia s BluePrint molecular diagnostics assay is the most widely available test providing molecular subtyping of individual breast cancers It is performed as part of the Symphony test panel Symphony also includes MammaPrint the fastest growing risk recurrence assay for breast cancer and the only one providing risk recurrence information that is based on prospective trials including patient outcome data e g the RASTER study MammaPrint provides definitive High Risk or Low Risk information about breast cancer recurrence without ambiguous intermediate results The BluePrint test building on the foundational prognostic precision of MammaPrint classifies breast cancer into one of four molecular subtypes Luminal A Luminal B HER2 type and Basal type BluePrint also provides information about neoadjuvant chemosensitivity that is responsiveness to chemotherapy more accurately than does an IHC FISH assessment The Agendia tests have substantial insurance coverage encompassing an estimated 170 million lives and including coverage by Medicare and regional and national insurers The Miami Breast Cancer Conference will be held Thursday March 6 through Sunday March 9 at the Fontainebleau Miami Beach Hotel in Miami Beach Fla About Agendia Agendia is a leading molecular diagnostic company that develops and markets FFPE based genomic diagnostic products which help support physicians with their complex treatment decisions Agendia s breast cancer Symphony suite was developed using unbiased gene selection analyzing the complete human genome ensuring 100 definitive results for cancer patients Symphony includes MammaPrint

    Original URL path: http://www.agendia.com/agendia-announces-upcoming-presentation-of-new-breast-cancer-data-on-molecular-subtyping/ (2016-05-01)
    Open archived version from archive



  •